Bone marrow-derived cell transplantation therapy for myocardial infarction: Lessons learned and future questions

American Journal of Transplantation

Volumn 11, Issue 11, 2011, Pages 2297-2301

  Dai, W ^a,b   Kloner, R A ^a,b  

^a GOOD SAMARITAN HOSPITAL   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Acutemyocardial infarction; Bone marrowderived cells; Cell transplantation therapy; Chronic heart failure

Indexed keywords

GRANULOCYTE COLONY STIMULATING FACTOR;

BONE MARROW CELL; CELL THERAPY; CELL TRANSPLANTATION; CELL TYPE; DOSE RESPONSE; DRUG MECHANISM; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEMATOPOIETIC STEM CELL; HUMAN; NONHUMAN; PRIORITY JOURNAL; REVIEW; STEM CELL MOBILIZATION;

ANIMALS; BONE MARROW TRANSPLANTATION; CARDIOMYOPATHIES; CELL TRANSDIFFERENTIATION; CHRONIC DISEASE; CLINICAL TRIALS AS TOPIC; HEMATOPOIETIC STEM CELL MOBILIZATION; HUMANS; MYOCARDIAL INFARCTION; MYOCARDIUM; TIME FACTORS; VENTRICULAR DYSFUNCTION, LEFT;

EID: 84857195643     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2011.03750.x     Document Type: Review

References (29)

1. Dai W, Hale SL, Martin BJ, et al. Allogeneic mesenchymal stem cell transplantation in postinfarcted rat myocardium: Short-and long-term effects. Circulation 2005; 112: 214-223. (Pubitemid 40982304)
2. Dai W, Hale SL, Kloner RA. Role of a paracrine action of mesenchymal stem cells in the improvement of left ventricular function after coronary artery occlusion in rats. Regen Med 2007; 2: 63-68. (Pubitemid 46824413)
3. Gnecchi M, He H, Noiseux N, et al. Evidence supporting paracrine hypothesis for Akt-modified mesenchymal stem cell-mediated cardiac protection and functional improvement. FASEB J 2006; 20: 661-669. (Pubitemid 44933310)
4. Lovell MJ, Yasin M, Lee KL, et al. Bone marrow mononuclear cells reduce myocardial reperfusion injury by activating the PI3K/Akt survival pathway. Atherosclerosis 2010; 213: 67-76.
5. Hatzistergos KE, Quevedo H, Oskouei BN, et al. Bone marrow mesenchymal stem cells stimulate cardiac stem cell proliferation and differentiation. Circ Res 2010; 107: 913-22.
6. Abdel-Latif A, Bolli R, Tleyjeh IM, et al. Adult bone marrow-derived cells for cardiac repair: A systematic review and meta-analysis. Arch Intern Med 2007; 167: 989-997. (Pubitemid 46835786)
7. Hofmann M,Wollert KC,Meyer GP, et al. Monitoring of bone marrow cell homing into the infarcted human myocardium. Circulation 2005; 111: 2198-2202. (Pubitemid 40632435)
8. Assmus B, Honold J, Schächinger V, et al. Transcoronary transplantation of progenitor cells after myocardial infarction. N Engl J Med 2006; 355: 1222-1232. (Pubitemid 44427446)
9. Assmus B, Tonn T, Seeger FH, et al. Red blood cell contamination of the final cell product impairs the efficacy of autologous bone marrow mononuclear cell therapy. J Am Coll Cardiol 2010; 55: 1385-1394.
10. Choi YH, Kurtz A, Stamm C. Mesenchymal stem cells for cardiac cell therapy. Hum Gene Ther 2011; 22: 3-17.
11. Hare JM, Traverse JH, Henry TD, et al. A randomized, double-blind, placebo-controlled, dose-escalation study of intravenous adult human mesenchymal stem cells (prochymal) after acute myocardial infarction. J Am Coll Cardiol 2009; 54: 2277-2286.
12. Astori G, Soncin S, Lo Cicero V, et al. Bone marrow derived stem cells in regenerativemedicine as advanced therapymedicinal products. Am J Transl Res 2010; 2: 285-295.
13. Meluzín J, Mayer J, Groch L, et al. Autologous transplantation of mononuclear bone marrow cells in patients with acute myocardial infarction: The effect of the dose of transplanted cells on myocardial function. Am Heart J 2006; 152: E9-e15.
14. Quyyumi AA, Waller EK, Murrow J, et al. CD34(+) cell infusion after ST elevation myocardial infarction is associated with improved perfusion and is dose dependent. Am Heart J 2011; 161: 98-105.
15. Zhang S, Sun A, Xu D, et al. Impact of timing on efficacy and safety of intracoronary autologous bone marrow stem cells transplantation in acute myocardial infarction: A pooled subgroup analysis of randomized controlled trials. Clin Cardiol 2009; 32: 458-466.
16. Sürder D, Schwitter J, Moccetti T, et al. Cell-based therapy for myocardial repair in patients with acute myocardial infarction: Rationale and study design of the SWiss multicenter Intracoronary stem cells study in acute myocardial infarction (SWISS-AMI). Am Heart J 2010; 160: 58-64.
17. Williams AR, Trachtenberg B, Velazquez DL, et al. Intramyocardial stem cell injection in patients with ischemic cardiomyopathy: Functional recovery and reverse remodeling. Circ Res 2011; 108: 792-796.
18. Schächinger V, Erbs S, Elsässer A, et al. Intracoronary bone marrow-derived progenitor cells in acute myocardial infarction. N Engl J Med 2006; 355: 1210-1221. (Pubitemid 44427445)
19. Miettinen JA, Ylitalo K, Hedberg P, et al. Determinants of functional recovery after myocardial infarction of patients treated with bone marrow-derived stem cells after thrombolytic therapy. Heart 2010; 96: 362-367.
20. Bai Y, Sun T, Ye P. Age, gender and diabetic status are associated with effects of bone marrow cell therapy on recovery of left ventricular function after acute myocardial infarction: A systematic review and meta-analysis. Ageing Res Rev 2010; 9: 418-423.
21. Brunskill SJ, Hyde CJ, Doree CJ, et al. Route of delivery and baseline left ventricular ejection fraction, key factors of bone-marrowderived cell therapy for ischaemic heart disease. Eur J Heart Fail 2009; 11: 887-896.
22. GyöngyösiM, Lang I, DettkeM, et al. Combined delivery approach of bone marrow mononuclear stem cells early and late after myocardial infarction: The MYSTAR prospective, randomized study. Nat Clin Pract Cardiovasc Med 2009; 6: 70-81.
23. Yao K, Huang R, Sun A, et al. Repeated autologous bone marrow mononuclear cell therapy in patients with large myocardial infarction. Eur J Heart Fail 2009; 11: 691-698.
24. Leistner DM, Fischer-Rasokat U, Honold J, et al. Transplantation of progenitor cells and regeneration enhancement in acute myocardial infarction (TOPCARE-AMI): Final 5-year results suggest long-term safety and efficacy. Clin Res Cardiol 2011 [Epub ahead of print].
25. Meyer GP, Wollert KC, Lotz J, et al. Intracoronary bone marrow cell transfer after myocardial infarction: Eighteen months' followup data from the randomized, controlled BOOST (BOne marrOw transfer to enhance ST-elevation infarct regeneration) trial. Circulation 2006; 113: 1287-1294. (Pubitemid 43739450)
26. Meyer GP, Wollert KC, Lotz J, et al. Intracoronary bone marrow cell transfer after myocardial infarction: 5-year follow-up from the randomized-controlled BOOST trial. Eur Heart J 2009; 30: 2978-2984.
27. Schlüter KD, Maxeiner H, Wenzel S. Mechanisms that regulate homing function of progenitor cells in myocardial infarction. Minerva Cardioangiol 2009; 57: 203-217.
28. Reffelmann T, Könemann S, Kloner RA. Promise of blood-and bone marrow-derived stem cell transplantation for functional cardiac repair: Putting it in perspective with existing therapy. J Am Coll Cardiol 2009; 53: 305-308.
29. Povsic TJ, O'Connor CM. Cell therapy for heart failure: The need for a new therapeutic strategy. Expert Rev Cardiovasc Ther 2010; 8: 1107-1126.